المؤلفون: Coleman RL; US Oncology Research, Texas Oncology, The Woodlands, Texas, USA rcoledude@mac.com., Lorusso D; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Oaknin A; Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Cecere SC; Department of Experimental Uro-Gynecological Oncology, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy., Denys H; Ghent University Hospital, Ghent, Belgium., Colombo N; European Institute of Oncology IRCCS Library, Milan, Italy.; University of Milan-Bicocca, Milan, Italy., van Gorp T; Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium., Konner JA; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Romeo Marin M; Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain., Harter P; KEM Kliniken Essen-Mitte, Essen, Germany., Murphy C; Cancer Centre and Cancer Trials, Bon Secours Hospital Cork, Cork, Ireland., Wang Y; ImmunoGen Inc, Waltham, Massachusetts, USA., Esteves B; ImmunoGen Inc, Waltham, Massachusetts, USA., Method M; ImmunoGen Inc, Waltham, Massachusetts, USA., Matulonis U; Dana Farber Cancer Institute, Boston, Massachusetts, USA.

المصدر: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2024 Aug 05; Vol. 34 (8), pp. 1119-1125. Date of Electronic Publication: 2024 Aug 05.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Multicenter Study

بيانات الدورية: Publisher: BMJ Country of Publication: England NLM ID: 9111626 Publication Model: Electronic Cited Medium: Internet ISSN: 1525-1438 (Electronic) Linking ISSN: 1048891X NLM ISO Abbreviation: Int J Gynecol Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/pathology , Ovarian Neoplasms*/mortality , Folate Receptor 1*/metabolism , Maytansine*/analogs & derivatives , Maytansine*/therapeutic use , Maytansine*/administration & dosage , Drug Resistance, Neoplasm* , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Immunoconjugates*/administration & dosage , Immunoconjugates*/adverse effects , Immunoconjugates*/therapeutic use, Humans ; Female ; Middle Aged ; Aged ; Adult ; Aged, 80 and over

المؤلفون: Richardson DL; Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Sarah Cannon Research Institute, Nashville, TN, United States. Electronic address: debra-richardson@ouhsc.edu., Moore KN; Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Sarah Cannon Research Institute, Nashville, TN, United States. Electronic address: kathleen-moore@ouhsc.edu., Vergote I; University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium. Electronic address: ignace.vergote@uzleuven.be., Gilbert L; McGill University Health Center-Research Institute, Montréal, Québec, Canada. Electronic address: lucy.gilbert@mcgill.ca., Martin LP; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States. Electronic address: lainie.martin@pennmedicine.upenn.edu., Mantia-Smaldone GM; Fox Chase Cancer Center, Philadelphia, PA, United States. Electronic address: gina.mantia-smaldone@fccc.edu., Castro CM; Massachusetts General Hospital, Boston, MA, United States. Electronic address: cmcastro@mgh.harvard.edu., Provencher D; Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada. Electronic address: diane.provencher.med@ssss.gouv.qc.ca., Matulonis UA; Dana-Farber Cancer Institute, Boston, MA, United States. Electronic address: ursula_matulonis@dfci.harvard.edu., Stec J; ImmunoGen, Inc., Waltham, MA, United States. Electronic address: james.stec@immunogen.com., Wang Y; ImmunoGen, Inc., Waltham, MA, United States. Electronic address: yuemei.wang@immunogen.com., Method M; ImmunoGen, Inc., Waltham, MA, United States. Electronic address: michael.method@immunogen.com., O'Malley DM; The Ohio State University, James Comprehensive Cancer Center, Columbus, OH, United States. Electronic address: david.o'malley@osumc.edu.

المصدر: Gynecologic oncology [Gynecol Oncol] 2024 Jun; Vol. 185, pp. 186-193. Date of Electronic Publication: 2024 Mar 05.

نوع المنشور: Journal Article; Clinical Trial, Phase I; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Bevacizumab*/administration & dosage , Bevacizumab*/adverse effects , Carboplatin*/administration & dosage , Carboplatin*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/pathology , Folate Receptor 1* , Maytansine*/analogs & derivatives , Maytansine*/adverse effects , Maytansine*/administration & dosage , Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use , Immunoconjugates*/administration & dosage , Immunoconjugates*/adverse effects , Carcinoma, Ovarian Epithelial*/drug therapy, Humans ; Female ; Middle Aged ; Aged ; Adult ; Progression-Free Survival ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/pathology ; Fallopian Tube Neoplasms/drug therapy ; Aged, 80 and over ; Peritoneal Neoplasms/drug therapy ; Thrombocytopenia/chemically induced

المؤلفون: Abel AC; Laboratory of Biomolecular Research, Department of Biology and Chemistry, Paul Scherrer Institute, Villigen, Switzerland; Biozentrum, University of Basel, Basel, Switzerland., Mühlethaler T; Biozentrum, University of Basel, Basel, Switzerland., Dessin C; Organic and Bioorganic Chemistry, Department of Chemistry, Bielefeld University, Bielefeld, Germany., Schachtsiek T; Organic and Bioorganic Chemistry, Department of Chemistry, Bielefeld University, Bielefeld, Germany., Sammet B; Organic and Bioorganic Chemistry, Department of Chemistry, Bielefeld University, Bielefeld, Germany., Sharpe T; Biozentrum, University of Basel, Basel, Switzerland., Steinmetz MO; Laboratory of Biomolecular Research, Department of Biology and Chemistry, Paul Scherrer Institute, Villigen, Switzerland; Biozentrum, University of Basel, Basel, Switzerland., Sewald N; Organic and Bioorganic Chemistry, Department of Chemistry, Bielefeld University, Bielefeld, Germany. Electronic address: norbert.sewald@uni-bielefeld.de., Prota AE; Laboratory of Biomolecular Research, Department of Biology and Chemistry, Paul Scherrer Institute, Villigen, Switzerland. Electronic address: andrea.prota@psi.ch.

المصدر: The Journal of biological chemistry [J Biol Chem] 2024 Jun; Vol. 300 (6), pp. 107363. Date of Electronic Publication: 2024 May 10.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Inc. on behalf of American Society for Biochemistry and Molecular Biology Country of Publication: United States NLM ID: 2985121R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1083-351X (Electronic) Linking ISSN: 00219258 NLM ISO Abbreviation: J Biol Chem Subsets: MEDLINE

مواضيع طبية MeSH: Tubulin*/chemistry , Tubulin*/metabolism , Maytansine*/chemistry , Maytansine*/analogs & derivatives, Humans ; Crystallography, X-Ray ; Binding Sites ; Microtubules/metabolism ; Microtubules/chemistry ; Vinca Alkaloids/chemistry ; Vinca Alkaloids/metabolism

المؤلفون: Romero D; Nature Reviews Clinical Oncology, . nrclinonc@nature.com.

المصدر: Nature reviews. Clinical oncology [Nat Rev Clin Oncol] 2024 Jun; Vol. 21 (6), pp. 402.

نوع المنشور: News

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101500077 Publication Model: Print Cited Medium: Internet ISSN: 1759-4782 (Electronic) Linking ISSN: 17594774 NLM ISO Abbreviation: Nat Rev Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Ovarian Epithelial*/drug therapy , Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/pathology , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Maytansine*/analogs & derivatives , Maytansine*/therapeutic use , Maytansine*/adverse effects , Immunoconjugates*/therapeutic use , Immunoconjugates*/adverse effects, Humans ; Female

المؤلفون: Kokori E; Department of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria., Olatunji G; Department of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria., Komolafe R; Department of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria., Abraham IC; Department of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria., Ukoaka B; Department of Internal Medicine, Asokoro District Hospital, Abuja, Nigeria., Samuel O; Department of Medicine and Surgery, Lagos State Health Service Commission, Lagos, Nigeria., Ayodeji A; Department of Medicine and Surgery, Olabisi Onabanjo University, Ogun, Nigeria., Ogunbowale I; Department of Medicine and Surgery, Babcock University Teaching Hospital, Ogun, Nigeria., Ezenwoba C; Department of Medicine and Surgery, Afe Babalola University, Ado-ekiti, Ekiti, Nigeria., Aderinto N; Department of Medicine and Surgery, Ladoke Akintola University of Technology, Ogbomoso, Nigeria.

المصدر: Medicine [Medicine (Baltimore)] 2024 May 17; Vol. 103 (20), pp. e38132.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE

مواضيع طبية MeSH: Ovarian Neoplasms*/drug therapy , Maytansine*/analogs & derivatives , Maytansine*/therapeutic use , Maytansine*/adverse effects , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Drug Resistance, Neoplasm* , Immunoconjugates*/therapeutic use , Immunoconjugates*/adverse effects, Humans ; Female ; Folate Receptor 1 ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/adverse effects

المؤلفون: Bonilla L; Health Sciences North, Sudbury, Ontario, Canada., Kasherman L; Department of Medical Oncology, Illawarra Cancer Care Centre, Wollongong, New South Wales, Australia., Manso L; Department of Medical Oncology, 12 de Octubre University Hospital, Madrid, Comunidad de Madrid, Spain., Madariaga A; Department of Medical Oncology, 12 de Octubre University Hospital, Madrid, Comunidad de Madrid, Spain ainhoa.madariaga@salud.madrid.org.

المصدر: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2024 Apr 01; Vol. 34 (4), pp. 478-479. Date of Electronic Publication: 2024 Apr 01.

نوع المنشور: Editorial

بيانات الدورية: Publisher: BMJ Country of Publication: England NLM ID: 9111626 Publication Model: Electronic Cited Medium: Internet ISSN: 1525-1438 (Electronic) Linking ISSN: 1048891X NLM ISO Abbreviation: Int J Gynecol Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Maytansine*/adverse effects , Maytansine*/analogs & derivatives , Immunoconjugates* , Ovarian Neoplasms*, Humans ; Female ; Antibodies, Monoclonal, Humanized

المؤلفون: Cheng CN; School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan., Liao HW; Department of Pharmacy, National Yang Ming Chiao Tung University, Taipei, Taiwan., Lin CH; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Department of Medical Oncology, National Taiwan University Hospital, Cancer Center Branch, Taipei, Taiwan., Chang WC; Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan., Chen IC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Department of Medical Oncology, National Taiwan University Hospital, Cancer Center Branch, Taipei, Taiwan., Lu YS; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Kuo CH; School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; The Metabolomics Core Laboratory, Centers of Genomic and Precision Medicine, National Taiwan University, Taiwan; Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: kuoch@ntu.edu.tw.

المصدر: Analytica chimica acta [Anal Chim Acta] 2024 May 15; Vol. 1303, pp. 342537. Date of Electronic Publication: 2024 Mar 25.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0370534 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4324 (Electronic) Linking ISSN: 00032670 NLM ISO Abbreviation: Anal Chim Acta Subsets: MEDLINE

مواضيع طبية MeSH: Percutaneous Coronary Intervention* , Immunoconjugates* , Maytansine*/therapeutic use, Humans ; Irinotecan ; Chromatography, Liquid ; Liquid Chromatography-Mass Spectrometry ; Tandem Mass Spectrometry

المؤلفون: Bogani G; Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy bogani.giorgio@gmail.com., Coleman RL; Gynecologic Oncology, Texas Oncology Houston Memorial City, Shenandoah, Texas, USA., Vergote I; Department of Gynecology and Obstetrics, Gynecologic Oncology, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium., van Gorp T; Gynaecological Oncology, KU Leuven University Hospitals Leuven, Leuven, Belgium., Ray-Coquard I; Centre Leon Berard, LYON CEDEX 08, Centre, France.; Hesper lab, Université Claude Bernard Lyon 1, Villeurbanne, France., Oaknin A; Vall d'Hebron Institute of Oncology, Barcelona, Spain., Matulonis U; Dana Farber Cancer Institute, Boston, Massachusetts, USA., O'Malley D; The Ohio State University Comprehensive Cancer Center Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio, USA., Raspagliesi F; Deparment of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Scambia G; Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy., Monk BJ; Virginia G Piper Cancer Center - Biltmore Cancer Center, Phoenix, Arizona, USA.

المصدر: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2024 Apr 01; Vol. 34 (4), pp. 469-477. Date of Electronic Publication: 2024 Apr 01.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: BMJ Country of Publication: England NLM ID: 9111626 Publication Model: Electronic Cited Medium: Internet ISSN: 1525-1438 (Electronic) Linking ISSN: 1048891X NLM ISO Abbreviation: Int J Gynecol Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Ovarian Neoplasms*/pathology , Maytansine*/analogs & derivatives , Immunoconjugates* , Antibodies, Monoclonal, Humanized*, Humans ; Female ; Drug Resistance, Neoplasm ; Neoplasm Recurrence, Local/drug therapy ; Carcinoma, Ovarian Epithelial/drug therapy ; Folate Receptor 1/therapeutic use

المؤلفون: Vasilevich NI; Shenzhen Academy of Peptide Targeting Technology at Pingshan and Shenzhen Tyercan Bio-Pharm Co., Ltd, Shenzhen, Guangdong, 518118, China. Electronic address: nvasile2003@yahoo.com., Jiang H; Shenzhen Academy of Peptide Targeting Technology at Pingshan and Shenzhen Tyercan Bio-Pharm Co., Ltd, Shenzhen, Guangdong, 518118, China., Xiao H; Shenzhen Academy of Peptide Targeting Technology at Pingshan and Shenzhen Tyercan Bio-Pharm Co., Ltd, Shenzhen, Guangdong, 518118, China., Feng K; Shenzhen Academy of Peptide Targeting Technology at Pingshan and Shenzhen Tyercan Bio-Pharm Co., Ltd, Shenzhen, Guangdong, 518118, China., Jian C; Shenzhen Academy of Peptide Targeting Technology at Pingshan and Shenzhen Tyercan Bio-Pharm Co., Ltd, Shenzhen, Guangdong, 518118, China., Chen C; Shenzhen Academy of Peptide Targeting Technology at Pingshan and Shenzhen Tyercan Bio-Pharm Co., Ltd, Shenzhen, Guangdong, 518118, China., Li M; Shenzhen Academy of Peptide Targeting Technology at Pingshan and Shenzhen Tyercan Bio-Pharm Co., Ltd, Shenzhen, Guangdong, 518118, China., Chen Z; Shenzhen Academy of Peptide Targeting Technology at Pingshan and Shenzhen Tyercan Bio-Pharm Co., Ltd, Shenzhen, Guangdong, 518118, China., Pang L; Shenzhen Academy of Peptide Targeting Technology at Pingshan and Shenzhen Tyercan Bio-Pharm Co., Ltd, Shenzhen, Guangdong, 518118, China., Li X; Shenzhen Academy of Peptide Targeting Technology at Pingshan and Shenzhen Tyercan Bio-Pharm Co., Ltd, Shenzhen, Guangdong, 518118, China., Chestkov AV; Shenzhen Academy of Peptide Targeting Technology at Pingshan and Shenzhen Tyercan Bio-Pharm Co., Ltd, Shenzhen, Guangdong, 518118, China., Sun AH; Department of Pathology, Tulane University Health Sciences Center, Tulane Cancer Center, New Orleans, LA70112, USA., Xu W; Department of Pathology, Tulane University Health Sciences Center, Tulane Cancer Center, New Orleans, LA70112, USA., Fuselier JA; Peptide Research Labs, Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA70112, USA., Coy DH; Peptide Research Labs, Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA70112, USA., Sun L; Shenzhen Academy of Peptide Targeting Technology at Pingshan and Shenzhen Tyercan Bio-Pharm Co., Ltd, Shenzhen, Guangdong, 518118, China; Peptide Research Labs, Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA70112, USA. Electronic address: peptide612@gmail.com.

المصدر: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2024 Feb 12; Vol. 696, pp. 149483. Date of Electronic Publication: 2024 Jan 09.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 0372516 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1090-2104 (Electronic) Linking ISSN: 0006291X NLM ISO Abbreviation: Biochem Biophys Res Commun Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/metabolism , Maytansine*, Humans ; Cell Line, Tumor ; Cell Cycle ; Cell Division

المؤلفون: Li X; Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China; Department of Pharmaceutical Analysis, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China., Wang Y; Nanjing Clinical Tech Laboratories Inc., 18 Zhilan Road, Jiangning District, Nanjing 211100, China., Hu W; Nanjing Jiening Pharmaceutical Technology, 18 Zhilan Road, Jiangning District, Nanjing 211100, China., Song Q; Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China; Department of Pharmaceutical Analysis, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China. Electronic address: songqinxin@cpu.edu.cn., Ding L; Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China; Nanjing Clinical Tech Laboratories Inc., 18 Zhilan Road, Jiangning District, Nanjing 211100, China; Nanjing Jiening Pharmaceutical Technology, 18 Zhilan Road, Jiangning District, Nanjing 211100, China; Department of Pharmaceutical Analysis, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China. Electronic address: dingli@cpu.edu.cn.

المصدر: Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2024 Mar 15; Vol. 240, pp. 115964. Date of Electronic Publication: 2024 Jan 12.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Country of Publication: England NLM ID: 8309336 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-264X (Electronic) Linking ISSN: 07317085 NLM ISO Abbreviation: J Pharm Biomed Anal Subsets: MEDLINE

مواضيع طبية MeSH: Immunoconjugates*/therapeutic use , Breast Neoplasms*/drug therapy , Breast Neoplasms*/metabolism , Maytansine*, Humans ; Female ; Ado-Trastuzumab Emtansine ; Chromatography, Liquid ; Antibodies, Monoclonal, Humanized/pharmacokinetics ; Receptor, ErbB-2/metabolism ; Tandem Mass Spectrometry ; Trastuzumab/therapeutic use ; Cytotoxins